down arrow

Vivos Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US92859E2072
USD
2.15
0.1 (4.88%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.042.15

52 Week

1.987.95
Valuation
Technical
Day's Volume

CASH

76.06 k

Shareholding (Mar 2025)

FII

0.52%

Held by 8 FIIs

DII

97.53%

Held by 2 DIIs

Promoter

0.00%

How big is Vivos Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Vivos Therapeutics, Inc. has a market capitalization of 12.72 million, with net sales of 14.63 million and a net profit of -11.24 million over the latest four quarters. The company has shareholder's funds of 7.95 million and total assets of 15.28 million as of Dec 24.

Market Cap: As of Jun 18, Vivos Therapeutics, Inc. has a market capitalization of 12.72 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Vivos Therapeutics, Inc. reported net sales of 14.63 million and a net profit of -11.24 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company has shareholder's funds amounting to 7.95 million and total assets of 15.28 million.

Read More

What does Vivos Therapeutics, Inc. do?

22-Jun-2025

Vivos Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $3 million and a net loss of $4 million as of March 2025. The company has a market cap of $12.72 million and key metrics indicate it is currently loss-making with no dividend yield.

Overview: <BR>Vivos Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 3 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 12.72 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.43 <BR>Return on Equity: -254.98% <BR>Price to Book: 2.89<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Should I buy, sell or hold Vivos Therapeutics, Inc.?

22-Jun-2025

Is Vivos Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 27, 2025, Vivos Therapeutics, Inc. shows a mildly bullish trend, supported by daily moving averages and monthly MACD, but caution is advised due to mildly bearish weekly MACD and Dow Theory, with the stock underperforming the S&P 500 year-to-date by -22.14%.

As of 27 August 2025, the technical trend for Vivos Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages indicating mild bullishness and monthly MACD showing a mildly bullish signal. However, the weekly MACD and Dow Theory are mildly bearish, suggesting some caution. The stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -22.14% versus the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 0%

  • The company has reported losses. Due to this company has reported negative ROE
2

Poor long term growth as Operating profit has grown by an annual rate -4.45% of over the last 5 years

 
3

Negative results in Jun 25

4

Risky - Negative EBITDA

5

Underperformed the market in the last 1 year

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 29 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.92

stock-summary
Return on Equity

-312.46%

stock-summary
Price to Book

6.27

Revenue and Profits:
Net Sales:
4 Million
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-52.54%
0%
-52.54%
6 Months
-8.9%
0%
-8.9%
1 Year
-39.94%
0%
-39.94%
2 Years
-89.2%
0%
-89.2%
3 Years
347.92%
0%
347.92%
4 Years
-96.24%
0%
-96.24%
5 Years
0%
0%
0.0%

Vivos Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Vivos Therapeutics Forms Death Cross, Signaling Potential Bearish Trend Ahead

Vivos Therapeutics Forms Death Cross, Signaling Potential Bearish Trend Ahead

Vivos Therapeutics, Inc. has recently encountered a technical event known as a Death Cross, indicating potential market sentiment shifts. The stock displays a mixed technical outlook, with varying trends in MACD, RSI, and Bollinger Bands. Year-to-date performance shows a decline, contrasting with broader market gains.

Read More

Is Vivos Therapeutics, Inc. technically bullish or bearish?

As of 27 August 2025, the technical trend for Vivos Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages indicating mild bullishness and monthly MACD showing a mildly bullish signal. However, the weekly MACD and Dow Theory are mildly bearish, suggesting some caution. The stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -22.14% versus the S&P 500's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-0.26%
EBIT Growth (5y)
-4.45%
EBIT to Interest (avg)
-16.84
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
5.88
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
14.97%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.98
EV to EBIT
-1.00
EV to EBITDA
-1.05
EV to Capital Employed
4.45
EV to Sales
0.77
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-446.49%
ROE (Latest)
-254.98%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (1.95%)

Foreign Institutions

Held by 8 Foreign Institutions (0.52%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 26.67% vs -18.92% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -28.21% vs -39.29% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.80",
          "val2": "3.00",
          "chgp": "26.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.60",
          "val2": "-3.70",
          "chgp": "-24.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.00",
          "val2": "-3.90",
          "chgp": "-28.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,273.60%",
          "val2": "-1,299.10%",
          "chgp": "2.55%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.70% vs -13.75% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 18.38% vs 42.86% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.00",
          "val2": "13.80",
          "chgp": "8.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.60",
          "val2": "-16.70",
          "chgp": "36.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "3.80",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.10",
          "val2": "-13.60",
          "chgp": "18.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-743.20%",
          "val2": "-1,253.20%",
          "chgp": "51.00%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
3.80
3.00
26.67%
Operating Profit (PBDIT) excl Other Income
-4.60
-3.70
-24.32%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.00
-3.90
-28.21%
Operating Profit Margin (Excl OI)
-1,273.60%
-1,299.10%
2.55%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 26.67% vs -18.92% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -28.21% vs -39.29% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
15.00
13.80
8.70%
Operating Profit (PBDIT) excl Other Income
-10.60
-16.70
36.53%
Interest
0.00
0.00
Exceptional Items
0.00
3.80
-100.00%
Consolidate Net Profit
-11.10
-13.60
18.38%
Operating Profit Margin (Excl OI)
-743.20%
-1,253.20%
51.00%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 8.70% vs -13.75% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 18.38% vs 42.86% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Vivos Therapeutics, Inc. stock-summary
stock-summary
Vivos Therapeutics, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."